PRODUCT INFORMATION

SARS-CoV-2 Neutralizing Antibody-Negative Human Serum

Item No. 31567

Overview

Contents: This vial contains 50 µl human serum.
Stability: ≥2 years at -80°C

Serum samples have been tested for ability to interfere with the ACE2/Spike RBD interaction using the Genscript cPass™ Surogate Virus Neutralization Test. Using a performance cutoff, the samples are deemed Neutralizing Antibody-Negative or Neutralizing Antibody-Positive.

Description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.[1-5] The SARS-CoV-2 genome encodes four structural proteins: surface glycoprotein, envelope, membrane, and nucleocapsid.[1,2] The surface glycoprotein, also known as the spike glycoprotein, is located on the outer envelope of the virion and binds to the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), which acts as the functional receptor for SARS-CoV-2 and facilitates virus cell entry.[1] SARS-CoV-2 infection can result in the production of SARS-CoV-2 neutralizing antibodies, which can prevent further viral entry and infection. [6,7] Plasma levels of SARS-CoV-2 spike glycoprotein-specific IgG antibodies have been reported to increase for at least four weeks after symptom onset followed by a decline in antibody levels over several months post-infection in both symptomatic and asymptomatic individuals.[6-9] This product contains human serum negative for SARS-CoV-2 neutralizing antibodies.

References

1. Kandeel, M., Ibrahim, A., Fayez, M., *et al.* From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* **92(6)**, 660-666 (2020).
2. Lu, R., Zhao, X., Li, J., *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **395(10224)**, 565-574 (2020).
3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* **24(4)**, 2012-2019 (2020).
4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* **191**, 145-147 (2020).
5. Yang, F., Shi, S., Zhu, J., *et al.* Analysis of 92 deceased patients with COVID-19. *J. Med. Virol.* (2020).
6. Wang, A., Zhang, L., Sang, L., *et al.* Kinetics of viral load and antibody response in relation to COVID-19 severity. *J. Clin. Invest.* (2020).
7. Xiang, F., Wang, X., He, X., *et al.* Antibody detection and dynamic characteristics in patients with coronavirus disease 2019. *Clin. Infect. Dis.* (2020).
8. Li, L., Tong, X., Chen, H., *et al.* Characteristics and serological patterns of COVID-19 convalescent plasma donors: Optimal donors and timing of donation. *Transfusion* (2020).
9. Long, Q.-X., Tang, X.-J., Shi, Q.-L., *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat. Med.* (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM